natgillin/translations-raw huggingface dataset:
The change in conductivity or pH may be gradual (gradient elution) or stepwise (step elution). 
Promjena provodljivosti ili pH može se izvoditi postupno (ispiranje u gradijentu) ili u zasebnim koracima (ispiranje u koracima).
a hybridoma capable of producing the antibody of any one of items 1 to 14 and 
Hibridom sposoban proizvesti protutijelo sukladno patentnom zahtjevu 1.
The isolated monoclonal antibody that selectively binds to ABCB5 of claim 1, wherein the isolated monoclonal antibody binds to human ABCB5. 
Izolirano monoklonsko protutijelo koje se selektivno veže na ABCBS5 prema zahtjevu 1, naznačeno time da se izolirano monoklonsko antitijelo veže na ljudski ABCBS5.
an inner bore having a diameter disposed along the longitudinal axis of the elongate structure; wherein the diameter of the inner bore is greater than a distance separating adjacent longitudinally extending ribs. 
unutrašnji otvor (50), koji ima promjer postavljen duž uzdužne osi izdužene strukture; naznačen time što je promjer unutrašnjeg otvora (50) veći od razmaka koji razdvaja susjedna uzdužno prostiruća rebra (82).
A compound of formula IV: 
Spoj sa formulom IV:
peripheral part 13, of the base part 5, is in communication with a pressure source (not shown), e.g. 
rubni dio 13 osnovnog dijela 5, povezan je s izvorom pritiska (koji nije prikazan), a to je npr.
All the animals had similar cholesterol and body weight at the beginning of the experiment. 
Sve životinje su imale sličan kolesterol i tjelesnu težinu na početku pokusa.
having at least two XRPD peaks, in terms of 2-theta, selected from about 18.4°, about 18.9°, about 21.8°, about 23.9°, about 29.2°, and about 38.7°; or 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji ima najmanje dva XRPD pika, u uvjetima na 2-teta +/- 0.2 °, izabrana od 18,4°, 18,9°, 21,8°, 23,9°, 29,2° i 38,7°.
A compound having the formula: or a stereoisomer, tautomer, pharmaceutically-acceptable salt, or solvate thereof. 
4 > ili stereoizomer, tautomer, farmaceutski-prihvatljiva sol, ili solvat tog spoja.
a centering cone arranged coaxially with the outer tube and the inner tube configured for sealing against the top end of a neck of a bottle to be filled; 
središnji stožac (28) koji je organiziran koaksijalno s vanjskom cijevi (24) i unutarnjom cijevi (26) i načinjen je da bude pričvršćen za vrh grla boce koja se puni;
and wherein step c) comprises incubating said liquid with one or more glucose fermenting microorganisms capable of fermenting glucose to an organic acid, or incubating said liquid with an enzyme or a mixture of enzymes capable of catalyzing conversion of glucose to form an organic acid, thereby forming organic acid in the starting liquid. 
inkubiranje navedene tekućine s jednim ili više mikroorganizama koji fermentiraju glukozu koji su sposobni fermentirati glukozu u organsku kiselinu; ili inkubiranje navedene tekućine s enzimom ili smjesom enzima sposobnima katalizirati pretvaranje glukoze tako da nastane organska kiselina, i
W is L-Y-glutamyl or L-Y-glutamylglycyl; X is optionally substituted C5-6 cycloalkyl, optionally substituted C5-6 heterocycloalkyl, optionally substituted phenyl, or optionally substituted C5-6 heteroaryl; 
Spoj iz zahtjeva lili 2, naznačen time, da Y je po izboru supstituirani Cs.g cikloalkil, po izboru supstituirani Cs5.4 cikloheteroalkil, po izboru supstituirani fenil, po izboru supstituirani Cs.g heteroaril.,
Another iteration of this embodiment relates to cations wherein one or more of Ra, Rb and Rc are chosen from hydrogen, unsubstituted C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl or substituted C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl. 
Spoj sukladno zahtjevu 1, pri čemu je A supstituirano jednim ili više R'" jedinica neovisno odabranih između: i) C,-Cy linearni, C3-Cy> razgranati, ili C3-Cy2 ciklički alkil, alkenil, 1 alkinil; ii) Cs ili Cig aril; ili) Cz ili Ci; alkilenaril; iV) Ci-Cg heterociklički prstenovi;
a first heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen with at least 80% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: 1, 3, 5, 32, 34 or 36; and 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da polinukleotid koji kodira NDV-F ima najmanje 90% identiteta sekvence prema SEQ ID NO: 1, 8, 49, 51 ili 53.
A method according to any one of claims 1 - 4, wherein the concentration of the basic amino acid or derivative thereof is at least 1 mM and sufficient to prevent or reduce aggregation of the Enteroviral particles is maintained throughout the entire duration of at least one of steps b), c) and d). 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 4, naznačen time što je koncentracija bazne aminokiseline 1li njezinog derivata najmanje 1 mM i dovoljna je da spriječi ili smanji agregaciju enterovirusnih čestica i održava se tijekom cjelokupnog trajanja najmanje jednog od koraka b), c) i d).
A method according to claim 1, wherein by atmospheric plasma pretreated adhesion method applied glue or adhesive amount in weight is significantly less than non atmospheric plasma pretreated adhesion method applied glue or adhesive amount, wherein the bonding strength of atmospheric plasma pretreated bonded materials and non atmospheric plasma pretreated bonded materials are essentially the same. 
Metoda u skladu sa patentnim zahtjevom 1, gdje je masa primijenjenog adheziva u metodi adhezije zasnovanoj na tretmanu atmosferskom plazmom značajno manja nego u metodi adhezije bez tretmana atmosferskom plazmom, gdje jačina vezivanja vezanih materijala tretiranih atmosferskom plazmom i vezanih materijala tretiranih neatmosferskom plazmom su suštinski iste.
an antisense oligomer that hybridizes under high stringent conditions to an oligonucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene. 
(£) antisensni oligomer sastavljen od nukleotidne sekvence koja ima najmanje 80% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 1 ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
A pharmaceutical composition comprising the polypeptide according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent and/or excipient. The pharmaceutical composition according to claim 9, further comprising an additional antibacterial agent, antifungal agent, antiviral agent, or antiparasitic agent. 
Farmaceutski pripravak koji sadrži polipeptid sukladno bilo kojem od patentnih zahtjeva 1-3 ili njegovu farmaceutski prihvatljivu sol, molekulu nukleinske kiseline sukladno patentnom zahtjevu 4 i/ili vektor sukladno patentnom zahtjevu 5 i najmanje jedan farmaceutski prihvatljivi nosač, otapalo i/ili ekscipijens.
The compound according to claim 1 wherein R2 is a group (a). 
Spoj prema zahtjevu 1, naznačen time, da R? je skupina (a).
or a pharmaceutically acceptable salt thereof, wherein R1 is H, a linear or branched alkyl having 1 to 5 carbon atoms, a terminal alkenyl having 1 to 5 carbon atoms, or —CH(CH3)(CH2)3CH(CH3)2. 
M4 =: (Formula A) naznačena time, što RI je H, linearni ili razgranati alkil ili terminalmi alkil koji ima 1 do 5 atoma ugljika ili - CI(CH3X(CH2)sCH(CHs)2.
Subsequently, the means for creating a vacuum start aspirating air within an open pneumatic circuit (FIG. 4), which branches off in such a way as to reach the using devices, i.e. the pair of suction cups 3, 4, the third suction cup 5, the fourth gripping suction cup 12 and the chambers 27, 37 present inside the guide 6 . 
Nakon toga sredstvo za stvaranje vakuuma počinje usisavati zrak u otvorenom pneumatskom krugu (slika 3), pri čemu je to sredstvo razgranato na takav način da dopire do uređaja koji se koriste, to jest do para usisnih čašica 3, 4, do treće usisne čašice 5, do četvrte zahvatne usisne čašice 12 1 do komora 27, 37 koje se nalaze u vodilici 6.
provided that, when Ar2 is A1), combinations of the substituents R6, R7 and R8 exclude a combination of a hydrogen atom and a halogen atom. 
tako da, kada Ar2 je A1), kombinacije supstituenata R6, R7 i R8 isključuju kombinaciju atoma vodika i halogen atom.
Methods for detecting the presence of IL-2 in a composition and for quantifying it are known in the art. 
Metode za detektiranje prisutnosti IL-2 u sastavu i za njihovo kvantificiranje su poznate u struci.
The method of claim 1, comprising determining the presence of H-Ras mutation in a sample from said subject. The method of claim 3, wherein said sample is a tumor biopsy. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži utvrđivanje pristunosti H-Ras mutacije u uzorku uzetom od navedenog subjekta.
The method comprises providing to that person an alcoholic beverage comprising water and ethanol, wherein at least 5 mole percent of the ethanol is a deuterated alcohol according to Formula 1. 
Alkoholno piće prema patentnom zahtjevu 1, u kome najmanje 5 molarnih postotaka etanola predstavlja deuterirani alkohol koji ima formulu ili ili ili formulu CD2CD;OH.
The antibody of claim 1 or claim 2, wherein the antibody further comprises an amino acid substitution of L235E and / or P331 S. 
Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time da protutijelo nadalje sadrži supstituciju amino kiseline od L235E i / ili P331 S.
The heterodimeric, conditionally active CAR of claim 1, wherein the order of the domains in the first polypeptide from the amino terminus to the carboxyl terminus is: the first member of the specific binding domain, the transmembrane domain, the first co-stimulatory domain and the first member of the dimerization pair. 
chimeric antigen receptor), naznačen time, da obuhvaća sljedeće: prvi polipeptid koji sadrži domenu koja veže antigen i koja obuhvaća varijabilno jednolančano područje protutijela, koje se specifično veže na CD19 ili antigen koji se eksprimira putem B-stanice, prvi član dimerizacijskog para, i prvu domenu transmembrane; i drugi polipeptid koji sadrži drugi član dimerizacijskog para, drugu domenu transmembrane i unutarstaničnu signalnu domenu;
The compound of claim 19 wherein the inflammatory pain is due to inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis. 
Spoj prema patentnom zahtjevu 20 pri čemu je upalni bol posljedica upalne bolesti crijeva, visceralne boli, migrene, postoperativne boli, osteoartritisa, reumatoidnog artritisa, boli u leđima, boli u donjem dijelu leda, boli u zglobovima, abdominalne boli, boli u grudima, rada, muskuloskeletnih bolesti, kožnih bolesti, zubobolje, povišene temperature, svraba anusa, opekotina od sunca, ugriza zmija, ugriza otrovnica, ugriza pauka, uboda insekta, neurogenog mjehura, intersticijalnog cistitisa, infekcije urinarnog trakta, rinitisa, kontaktnog dermatitisa/hipersenzitivnosti, svraba, ekcema, faringitisa, mukozitisa, enteritisa, sindroma iritabilnog crijeva, holecistitisa, pankreatitisa, postmastektomijskog sindroma boli, menstrualne boli, endometrioze, boli, boli zbog fizičke traume, glavobolje, sinusne glavobolje, tenzijske glavobolje, ili arahnoiditisa.
Thus, the “stable” phase need not always be the phase with the “globally” lowest free energy, but it often will be. 
Zato nije uvijek neophodno, ali je često potrebno, da "stabilna" faza uvijek ima "globalnu" najnižu slobodnu energiju.
The rack (23) extends into the chamber in a direction perpendicular to the motion of the plug and parallel with the face of the plug (19) and has a toothed portion. 
Uređaj prema bilo kojem od prethodnih Zahtjeva; gdje je klip (6) obično cjevastog oblika i ima teleskopski dio koji najmanje djelomično obuhvaća nizvodnu površinu čepa (19).
instructing the subscribed communication device to reconnect to the preferred network. The method of claim 1, wherein the determining step comprises determining the current location on the basis of the physical location of the subscribed communication device as determined using global positioning systems. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se korak određivanja sastoji u određivanju trenutne lokacije na osnovi fizičke lokacije pretplatničkog mobilnog komunikacijskog uređaja (10, 20, 101) kako je određena uz pomoć globalnih sustava lociranja.
The pharmaceutical composition of claim 6, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent. 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da je dodatno terapeutsko sredstvo odabrano od antikanceroznog spoja, analgetika, antiemetika, antidepresiva i protuupalnog sredstva.
The method of item 5 or 6, wherein said method converts MRD positive ALL into an MRD negative status. The method of any of items 5 to 7, wherein MRD is measured with quantitative detection of at least one of the cytogenetic abnormalities or rearrangements selected from the group consisting of: 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se MRD mjeri kvantitativnim opažanjem najmanje jedne od citogenetičkih abnormalnosti ili pregradnji, koje se bira iz skupine koju čine: 4(12;21)[TEL-AMLI];
For example, EP 1,176,195 by Hang et al. describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation or are devoid of fucosyl residues. Therefore, in one embodiment, the antibodies of the invention are produced by recombinant expression in a cell line which exhibit hypofucosylation or non-fucosylation pattern, for example, a mammalian cell line with deficient expression of the FUT8 gene encoding fucosyltransferase. 
Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da se proizvodi pomoću rekombinantne ekspresije u staničnoj liniji koja nema fukoziltransferazu, primjerice u staničnoj liniji sisavca s nedovoljnom ekspresijom gena FUTB8 koji kodira fukoziltransferazu, čime se povećava ADCC-djelovanje od tako proizvedenih protutijela, u usporedbi s ekspresijom stanične linije kod divlje vrste gena FUTB8.
The acidic conditions are preferably obtained by using compound (II) in the form of an organic acid addition salt, e.g. 
Kiseli uvjeti su prvenstveno dobiveni korištenjem spojeva (II) u obliku adicione soli s organskom kiselinom, npr.
10, 13125 Berlin (Germany) at the September 15, 2006. 
Glycotope GmbH, Robert-R&ssle-Strasse 10, 13125 Berlin, DE
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. The solid oral extended release pharmaceutical dosage form of item 88, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25%C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1, 4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja. Oralni farmaceutski oblik doziranja u krutom slanju sa produljenim otpuštanjem prema zahtjevu 3, naznačen time da je formulacija matrice sa produljenim otpuštanjem bila pohranjena na 40%C 1 75 % relativne vlažnosti (RH).
A host cell, comprising a nucleic acid or an expression vector according to Claim 2. 
Nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5 za uporabu u medicini.
Thus when the cam surface causes release of the latch keys from the latch fingers, stored potential energy in the wireline reacts suddenly to drive the jar mandrel further upwardly within the housing, causing a hammer member secured to the jar mandrel to strike an anvil defined within the housing and thereby confer an upwardly acting impulse on the housing, and hence any further part of the toolstring secured thereto. 
To znači da, kada nazubljena površina oslobodi zasun od prstena zasuna, uskladištena potencijalna energija u žicanoj vezi momentalno reagira tako da potiskuje vreteno udaraca prema gore unutar kućišta izazivajući da član čekića na vretenu udaraca udari o nakovanj, koji je smješten unutar kućišta, čime prenosi djelujući impuls prema gore na kućište i time svaki drugi dio alata koji je vezan za njega.
the coding unit of the depth greater than the current depth is predicted using the at least one prediction unit and is inverse-transformed using the at least one transformation unit, 
raščlanjivanje, iz toka bitova, kvantiziranih koeficijenata transformacije barem jedne transformacijske jedinice u jedinici za kodiranje;
The gastroretentive drug formulation of any of the preceding claims, wherein the inner layer has planar accordion geometry, and wherein the planar accordion geometry together with the presence of said polymers in the internal layer provides the internal layer with the necessary mechanical strength in gastric medium. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 1, pri čemu unutarnji sloj ima planarnu geometriju harmonike, i pri čemu planarna geometrija harmonike zajedno s prisutnošću navedenih polimera u unutarnjem slju daje unutarnjem sloju značajnu mehaničku snagu.
polyurethanes; poly siloxanes. The intragastric balloon (10) as claimed in any one of the preceding claims, wherein the sealed container is made from one of the following: 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se taj zapečaćeni spremnik izrađuje od slijedećeg: polidimetil siloksana; politetrafluroetilena; polietilena; polietilena niske gustoće; polipropoliena; poliestera; poliamida.
Recombinant rat LH was prepared according to known methods, e.g., the method described by Hakola et aL., Molecular & Cellular Endocrinology (1997), 128, 47-56. 
Rekombinantni štakorski LH dobiven je poznatim postupcima, primjerice postupakom opisanim u Hakola i dr.: Molecular & Cellular Endocrinology, 128, 47-56, (1997.).
LA is unbranched or branched, linear alkyl having 1, 2, 3, or 4 C atoms wherein 1, 2 or 3 H atoms may be replaced by Hal (e.g., methyl, ethyl, and trifluoromethyl); and Hal is F, Cl, Br or I. 
LA je nerazgranati ili razgranati, linearni alkil koji ima 1, 2, 3, ili 4 C atoma pri čemu 1, 2 ili 3 H atoma mogu biti zamijenjeni sa Hal (npr., metil, etil, i trifluormetil); i Hal je F, Cl, Br ili I.
In some embodiments, the pressure applied in the compacting step is at least 25 bar, in particular at least 30 bar, more in particular at least 35 bar, still more in particular at least 40 bar, even more in particular at least 45 bar, or at least 50 bar. 
Postupak prema bilo kojem od prethodnih zahtjeva gdje je tlak u koraku stlačivanja barem 25 bara, točnije barem 30 bara, točnije barem 35 bara, još točnije barem 40 bara, još točnije barem 45 bara, ili barem 50 bara.
This can be seen in FIG. 3, which shows a portion of a composite structure which in practice is very much larger, of course. 
To se može vidjeti na slici 3, koja prikazuje dio kompozitne strukture koja je u praksi naravno vrlo mnogo veća.
the mole fraction of the structural unit of Formula 1 in the polymer is at least 0.87 based on the total number of moles of the structural units of Formulae 1, 2, and 3, calculated from the amounts of monomers used in the polymerization reaction, and the mole ratio of the structural unit of Formula 2 to the structural unit of Formula 3 is from 0.2:1 to 7:1, and Formula 1, Formula 2, and Formula 3 correspond to the following structures: wherein 
Farmaceutski pripravak naznačen time da sadrži sol umreženog polimera za kationsku izmjenu i od 10 tež.% do 40 tež.% ravnolančanog šećera bazirano na ukupnoj težini pripravka, te umreženi polimer za kationsku izmjenu sadrži strukturne jedinice koje odgovaraju Formulama 1 i 2, Formulama 1 i 3, ili Formulama 1, 2, i 3, pri čemu su Formula 1, Formula 2, i Formula 3 prikazane sa slijedećim strukturama: [image] pri čemu
Use of an oligonucleotide or oligonucleotide composition in the method of any one of claims 1-4, said oligonucleotide or the oligonucleotides of said composition comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 6, 44-48, 62-64, 2, and 16-22 and variants thereof with a 5'-terminal and/or a 3'-terminal deletion of 1, 2, 3, 4 or 5 nucleotides. Kit, comprising 
oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 5 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri; i ii) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 44 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri;
Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. 
Primjeri takvih organskih soli su one s maleinskom, fumarinskom, benzojevom, askorbinskom, sukcinatnom, oksalnom, bi-metilensalicilnom, metansulfonskom, etandisulfonskom, acetatnom, propionskom, vinskom, salicilnom, limunskom, glukonskom, mliječnom, jabučnom, bedomovom, cimetnom, citrakoničnom, aspartatnom, palmitinskom, itakoničnom, glikolnom, p-aminobenzojevom, glutamatnom, benzensulfonskom i teofilin acetatnom kiselinom, kao i sa 8-haloteofilinom, na primjer 8-bromoteofilin.
Similarly, WO 02/085119 describes a dosage form for intra-oral delivery of nicotine comprising a hydroxypropylmethylcellulose film. 
Slično tome, WO 02/085119 opisuje oblik doze za intra-oralnu primjenu hidroksipropilmetilceluloznog filma koji sadrži nikotin.
and pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. 
i njihove farmaceutski prikladne kiselinske adicijske soli, njihovi optički čisti enantiomeri, racemati ili njihove dijastereomerne mješavine.
an antibody or antigen-binding fragment thereof that binds to an epitope comprising residues 82-89 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO: 12; and 
aminokiselinske ostatke regije koja određuje komplementarnost (CDR) u SEQ ID NO:2 i aminokiselinske ostatke regije koja određuje komplementarnost (CDR) u SEQ ID NO:4; ili
Specific thiazolidin-4-one derivatives according to formula (II) are: 
Novi derivati tiazolidin-4-ona Opće formule (II) t>&